Filing Details
- Accession Number:
- 0000950170-25-064711
- Form Type:
- 13D Filing
- Publication Date:
- 2025-05-05 20:00:00
- Filed By:
- Foundation Fighting Blindness Retinal Degeneration Fund
- Company:
- Opus Genetics Inc. (NYSEMKT:IRD)
- Filing Date:
- 2025-05-06
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | 0 | 9,492,171 | 0 | 9,492,171 | 9,492,171 | 15.9% |
| Foundation Fight Blindness, Inc. | 0 | 9,492,171 | 0 | 9,492,171 | 9,492,171 | 15.9% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
|
Opus Genetics, Inc. (Name of Issuer) |
Common Stock, $0.0001 par value per share (Title of Class of Securities) |
67577R102 (CUSIP Number) |
Russell Kelley, Managing Dir. Foundation Fighting Blindness RD Fund, 223 S. West Street, Suite 900 Raleigh, NC, 27603 919-610-2064 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
04/30/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 67577R102 |
| 1 |
Name of reporting person
Foundation Fighting Blindness Retinal Degeneration Fund | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,492,171.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO, OO |
Comment for Type of Reporting Person:
Percent of class represented in Row (11) is based on 59,629,197 shares of common stock, $0.00001 par value per share (the "Common Stock") of Opus Genetics, Inc., a Delaware corporation (the "Issuer") outstanding, which is the sum of the converted Series A non-voting convertible preferred stock, $0.0001 par value per share (the Preferred Stock") plus 45,483,823 shares of Common Stock outstanding as of March 27, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 31, 2025.
SCHEDULE 13D
|
| CUSIP No. | 67577R102 |
| 1 |
Name of reporting person
Foundation Fight Blindness, Inc. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
MARYLAND
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,492,171.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person:
Percent of class represented in Row (11) is based on 59,629,197 shares of the Issuer's Common Stock outstanding, which is the sum of the converted Preferred Stock plus 45,483,823 shares of the Issuer's Common Stock outstanding as of March 27, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on March 31, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, $0.0001 par value per share | |
| (b) | Name of Issuer:
Opus Genetics, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
8 Davis Drive, Suite 220, Durham,
NORTH CAROLINA
, 27709. | |
Item 1 Comment:
This Amendment No. 1 on Schedule 13D amends the statement on Schedule 13D, dated October 29, 2024 (the "Original Schedule 13D"), which relates to the Common Stock of the Issuer, filed by the Reporting Persons.
This Amendment No. 1 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons as a result of automatic conversion of the Issuer's Preferred Stock on the third business day after the date that the Issuer's stockholders approved the conversion of the Preferred Stock into shares of the Issuer's Common Stock, which approval occurred on April 30, 2025.
| ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | 9,492,171 - 15.9% | |
| (b) | 9,492,171 | |
| (c) | Reference is made to the discussion in Item 3 of the Original Schedule 13D and the Form 3 filed by the Reporting Person on October 29, 2024 with the SEC pursuant to Section 16 of the Act and is available on the SEC's website at www.sec.gov. The information reported in the filings are expressly incorporated herein. | |
| (e) | Not Applicable. | |
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 5 - Joint Filing Agreement by and between the Reporting Persons. | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|